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12 Oral PresentationsAverage infused TNC/kg 107 was 2.9 (1.9–5.8) and 4.7 (0.6–9.1)
for the non-cultured and cultured cells respectively, and infused
CD34 cells/kg (105) was 2.2 (1.1–3.4) and 55 (9.1–136) respec-
tively. No toxicities directly attributable to the cultured product,
including infusional, increased acute GVHD, or graft failure
have been observed. Relatively rapid engraftment was observed
in 7 of 8 patients with a median time to engraftment of 16 days
(7 to 34), as compared to 25 days (16 to 48) in patients (n 5 17)
undergoing an identical transplant regimen here, but with 2 non-
cultured CBU. Relative contribution of the expanded and non-cul-
tured grafts over time was determined by a DNA-based assay on
peripheral blood, beginning day 7 post transplant. Engrafted my-
eloid cells present at day 7 were derived almost entirely from the
expanded unit in 7 patients. In 3 of 7, ANC . 500 was observed
at days 7, 9 and 16 and was mainly derived from the expanded
unit, whereas in the other 4 patients who achieved ANC . 500 at
day 13, 16, 20 and 21, myeloid engraftment at day 14 was derived
from the non-cultured cells. Persistent engraftment from the ex-
panded cells has been noted in 2 patients, one through 280 days
post transplant and one who is currently 125 days post transplant
in whom the expanded cells continue to dominate in CD33,
CD14 and CD56 sorted cell fractions. Average follow-up time is
287 days (range 56–680). One patient died on day 462 from com-
plications of VZV myelitis; all other patients are alive and in remis-
sion. Thus, improvement in early myeloid reconstitution may result
from provision of short term repopulating cells and/or of cells able
to facilitate engraftment of the non-cultured unit. These studies
continue with the goal of achieving consistent, rapid engraftment in
recipients of hematopoietic cell transplants to decrease morbidity
and mortality in the early post-transplant setting.
GVH/GVL
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TARGETED PROTECTION OF THE COLON IN THE ABSENCE OF DONOR
ANTIGEN-PRESENTING CELL -DERIVED INTERLEUKIN 23 ALLOWS FOR
SEPARATION OF GRAFT VERSUS HOST AND GRAFT VERSUS LEUKEMIA
EFFECTS
Das, R., Drobyski, W.R. Medical College of Wisconsin, Milwaukee, WI
Separation of graft versus leukemia (GVL) and graft versus host
(GVH) reactivity has been a longstanding but elusive goal in allo-
geneic bone marrow transplantation (BMT). Recent studies from
our laboratory have shown that donor APC-derived IL-23 secre-
tion has a critical role in mediating pathological damage in the co-
lon during GVHD, but has no protective effect in other GVHD
target organs such as the lung and liver. These results demonstrate
the feasibility of regional GVHD protection and raise the question
as to whether such localized protection might be a strategy to sep-
arate GVH and GVL responses. To directly address this question,
we employed a novel, clinically relevant murine model of chronic
myelogenous leukemia (CML). In this model, FVB animals that
have the bcr/abl oncogene under the control of a tetracycline-in-
ducible repressor are used as donor animals (i.e. CML mice).
Lethally irradiated normal FVB mice were transplanted with
equivalent numbers (107) of T cell depleted BM from B6 and
FVB CML animals. Withdrawal of tetracycline from the drinking
water induces expression of the bcr/abl oncogene and the devel-
opment of granulocytic hyperplasia and splenomegaly in
transplanted mice. Additional cohorts of animals were also trans-
planted with the same BM inoculum plus 3.5  106 T cells from
either wild type or IL-23-/- donors to determine if GVL and
GVH effects could be dissociated. Whereas mice that received ad-
junctive B6 T cells succumbed from fatal GVHD, animals trans-
planted with T cells from IL-23-/- mice had significantly
prolonged survival and no evidence of leukemia by blood counts
or pathological examination. In order to address the role of
IL-23 in the GVL response directed against leukemia with more
aggressive kinetics, similar studies were performed using a Balb-
derived A20 leukemia cell line. Transplantation with BM and
spleen cells from IL-23-/- donor mice resulted in significantly pro-
longed survival when compared to mice reconstituted with simi-
larly composed marrow grafts from wild type B6 animals. A
five–fold escalation of the A20 cell dose produced similar protec-
tive results in recipients of IL-23-/- marrow grafts. In conclusion,
these studies show that in the absence of donor APC-derived IL-23, GVHD can be significantly reduced without loss of the GVL
effect. Moreover, our results suggest that targeting of IL-23 may
be a viable clinical strategy to ameliorate that severity of GVHD
without abrogating a GVL response.26
FLAGELLIN, A TLR5 AGONIST, FACILITATES PRODUCTION OF
FOXP31CD41CD251 REGULATORY T CELLS TO MAINTAIN BALANCED
IMMUNE RECONSTITUTION IN ALLOGENEIC BMT WITHOUT GVHD
Hossain, M.S.1, Roback, J.D.2, Gewirtz, A.T.2, Waller, E.K.1 1Emory
University, Atlanta, GA; 2Emory University, Atlanta, GA
Background: Graft-vs-host disease (GvHD) and lyphopenia are
the major clinical problems in allogeneic bone marrow transplanta-
tion (BMT). Immunosuppressive drugs are used to control GvHD,
but immunosuppression is often incomplete and patients experience
drug-related toxicities. Donor foxp31CD251CD41 regulatory T
cells are also effective at controlling GvHD, but are expensive and
time consuming to produce. Flagellin, a bacterial protein and
a TLR5 agonist, can culminate production of proinflammatory cyto-
kines and chemokines. In this study we investigated whether flagellin
could facilitate thymic production of donor BM-derived
foxp31CD251CD41 regulatory T cells to control GvHD and reg-
ulate post BMT immune reconstitution.
Methods: Irradiated (11Gy) CB6F1 recipient received 5  106
T cell depleted BM and 5  106 splenocytes from naive C57BL/6
congenic donors. 50 micro gm flagellin/mouse was administered
i.p. 3 hours before irradiation and 24 hours after BMT. Recipients
that received no flagellin were used as control. After 701 days
post transplant recipients were infected with 5  103 pfu
MCMV i.p., sacrificed at different time points and lymphocytes
were harvested from spleen and thymus for analysis. Flow cytom-
etry was used to determine immune reconstitution, normal and
regulatory T cells.
Results: All flagellin-treated recipients survived without GvHD
for 66 days post transplant, while only 65% of the control mice sur-
vived and had chronic GvHD. The number of splenocytes was sig-
nificantly increased in flagellin-treated recipients compared to
control recipients (p 5 0.0006) on day 66-post transplant. Donor
spleen- and BM-derived CD41 and CD81T cells were significantly
higher in the spleen of flagellin-treated recipients compared to con-
trol mice. Flagellin-treated recipients had higher levels of both do-
nor spleen- and BM-derived anti-viral CD81 T cells in the spleen
compared to control recipients. The thymus of flagellin-treated
recipients produced donor spleen- and BM-derived T cells and
foxp31CD251CD41 regulatory T cells, while thymic functions
were severely reduced in control recipients.
Conclusion: Flagellin treatment successfully reduced GvHD, im-
proved survival, enhanced donor T-cell engraftment and produced
regulatory T cells in allo-BMT. Treated recipients had brisk and
persistent cellular immune responses against MCMV infection.
Hence, prophylactic use of flagellin is a novel therapeutic approach
to treat blood cancer patients with allogeneic BMT.27
LYMPHOCYTE RECOVERY IS A MAJOR DETERMINANT OF TRANSPLANT
OUTCOME AFTER MYELOABLATIVE TRANSPLANTATION IN PATIENTS
WITH MYELOID MALIGNANCIES RECEIVING MATCHED UNRELATED
STEM CELL ALLOGRAFTS
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A higher lymphocyte count one month after allogeneic stem cell
transplantation (SCT) is associated with better outcome in patients
transplanted from an HLA-identical sibling. However, a predictive
role of the day 30 post-transplant absolute lymphocyte count
(LC30) in unrelated transplants is not defined. We studied the rela-
tionship between LC30 and outcome in 102 patients with myeloid
leukemia receiving myeloablative SCT from matched unrelated do-
nors. Conditioning consisted of cyclophosphamide with Busulphan
(n 5 61) or total body irradiation (n 5 41). Immunosuppression
